anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It is widely recognized that foods, biodiversity, and human health are strongly interconnected, and many efforts have been made to understand the nutraceutical value of diet. In particular, diet can affect the progression of intestinal diseases, including inflammatory bowel disease (IBD) and intestinal cancer. In this context, we studied the anti-inflammatory and antioxidant activities of extracts obtained from a local endangered variety of Phaseolus vulgaris L. (Fagiola di Venanzio, FV). Using in vitro intestinal cell models, we evaluated the activity of three different extracts: soaking water, cooking water, and the bioaccessible fraction obtained after mimicking the traditional cooking procedure and gastrointestinal digestion. We demonstrated that FV extracts reduce inflammation and oxidative stress prompted by interleukin 1β through the inhibition of cyclooxygenase 2 expression and prostaglandin E2 production and through the reduction in reactive oxygen species production and NOX1 levels. The reported data outline the importance of diet in the prevention of human inflammatory diseases. Moreover, they strongly support the necessity to safeguard local biodiversity as a source of bioactive compounds.
The correct diagnosis of acute coronary syndrome (ACS) remains a frequent significant challenge for emergency physicians. Over eight million chest pain patients present annually and despite promising advances in diagnosis, over four percent of ACS patients are mistakenly discharged home. While the history and physical, cardiac risk factor assessment, ECG, and cardiac marker determination are all included in the assessment and risk stratification of patients presenting with possible ACS, this assessment is clearly far from perfect. Improved rapid and accurate means of assessment in this population in the ED are clearly needed.ED patients with chest discomfort will be screened and approached for study enrollment. Consenting patients meeting the study inclusion and exclusion criteria will be enrolled. Point-of-care serial cardiac marker measurements will be performed. Based on a web-based computerized randomization system, half (50%) the patients willundergo routine central laboratory testing only. Half (50%) of the patients will undergopoint-of-care markers performed in the ED in addition to routine central laboratory testing.In this second group, central laboratory test results will be blinded from the ED physicianuntil the disposition time. BNP will be blinded and not reported to physicians for the first 500 patients (Phase I). After the first 500 patients have been enrolled, an interim analysis will be performed to determine the clinical utility of BNP in patient assessment. After physician education of these results, the trial will resume for the remaining 500 patients (Phase II). In Phase II, BNP levels will be provided to the physicians using the same time and randomization format.The patients and their medical records will be followed for a period of thirty days and sixmonths after enrollment.
The present invention discloses traditional Chinese medicine capable of accelerating the exuviation of cultivated prawns and sterilizing water. A formula of the present invention comprises 19 kinds of traditional Chinese medicine, such as golden larch bark, lightyellow sophora root, solomonseal rhizome, etc., and a preparation method and a use method of the present invention are simple and practical. According to the formula, the preparation method and the use method, the medicine takes effect after the medicine is spread into a pond for raising prawns for 0.5 to 1 hour, and then, prawns start to exuviate. The medicine can sterilize water in a prawn pond by killing erythrasma, cutaneous fungi, anthrax bacilli, staphylococcus aureus, colibacillus, mumps viruses, etc. so as to clean water and provide a good growing environment for prawns. The present invention has the advantages of rapid exuviation and good environment, so the growing cycle of prawns can be considerably shortened, requirements of the market are satisfied, and economic benefits and people's living standard are improved. The present invention is suitable for the cultivation of various prawns.
A method for providing medical diagnostics comprises providing access to one or more platforms capable of distributing one or more applications for implementing a method. The method comprises retrieving, with the aid of a processor, one or more images from an image database or an imaging device. The one or more images can define a set of images. Next, with the aid of a processor, whether each of the images is of medical interest to a reviewing physician is determined. One or more images can then be provided to a display and analysis system for review by a reviewing physician. The one or more images can be provided with an image that is representative of the set of images.
PURPOSE: To enable a patient to consult a doctor through the screen of a terminal equipment by installing this terminal equipment at a place out of a consultation room and connecting the terminal equipment to a terminal equipment installed in the consultation room via a signal line. CONSTITUTION: A patient is detected at a patient detection part 10 of a terminal equipment (b) installed at a place out of a consultation room, and the patient identification information on a consultation ticket 11 is read at a reading part 12. The patient's chart is identified at a patient's chart identification part 1 and shown at a display part 3. A discrimination part 2 decides whether the patient's chart shows that the medical prescription is permitted for the patient with no judgement of the doctor. If the prescription is permitted, a medical prescription is outputted by a printer 18. Then the patient is photographed by a camera 17 and this image of the patient is converted into the still picture signals. These signals are switched to the signals received from a voice input part 15 and sent to a terminal equipment (a) of the consultation room via an input/output part 19.  The still picture signals received from an input/output part 8 undergo the necessary processing and are shown on a screen of the part 3. The voice signals are outputted through a voice output part 6. The doctor converts the image of a camera 7 into the still picture signals. The questions, etc., are inputted through a voice input part 5 and sent to the terminal equipment (b) after the proper switching. The images are shown at a display part 13 and the voices are outputted through a voice output part 16.
This invention provides an antiallergic composition. It is useful for preventing and treating allergy. It also provides a method of preparing antiallergic composition and its utilization such as foods, drinks, etc. A lactic acid fungus uses as an active ingredient of antiallergic composition. Wherein, lactic acid fungus presents the following characteristic: As the lymphocyte of the spleen of the little mouse of the albumin sensitization of when the culture medium contain albumin of the examined lactic acid fungus to carry on the cultivation, a lactic acid bacterium which shows an interleukin 12 productivity comparable to the case using L. paracasei KW3110 strain as a test lactic acid bacterium or at least 60% as much as the case using L. paracasei KW3110 strain and an interleukin 4 productivity less than 50% of the control case without adding any lactic acid bacteria. When cultured in an egg albumin-containing medium in which mouse spleen-origin lymphocytes having been sensitized with egg albumin are suspended. The method of obtaining the lactic acid bacterium with a high antiallergic activity, it is the active ingredient of the antiallergic composition. Furthermore, it utilizes the antiallergic composition in foods, drinks, etc. Consequently, it utilizes the antiallergic composition by processing it into an antiallergic preparation for oral administration.
Adolescent and young adult (AYA) cancer patients and survivors are a growing population due to more frequent diagnoses and improved survival. Fatigue is a common symptom experienced by cancer patients and it is often missed by health care professionals. Patient reported outcome measures (PROMs) can assist in evaluating patient reported fatigue. This systematic review aims to determine if AYA cancer patients report more fatigue than AYAs who have not been diagnosed with cancer. We used a subset of articles from a larger review that searched PubMed, EMBASE, CINAHL, and PsycINFO to determine which PROMs and domains are currently being used to evaluate AYA cancer. This study identified 175 articles related to PROMs in the AYA cancer population. Articles with PROMs reporting on fatigue/vitality were used in this review. From the original 175 articles, we identified 8 fatigue/vitality articles for this review. All eight articles found an increase in fatigue/decrease in vitality in the AYA cancer population compared to healthy controls. A meta-analysis was performed on four articles that used the same PROM tool (EORTC QLQ-C30). This found a statistically significant and clinically meaningful increase in mean fatigue of 12.5 95% confidence interval: 3.3-21.8 points (scale 0-100, higher number indicates more fatigue) in the AYA cancer group compared to healthy noncancer controls. Fatigue in the AYA cancer population is a significant issue, it is often undetected and underreported, and early interventions are needed to prevent the negative subsequent sequelae.
The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of ketorolac tromethamine may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs) (see PRECAUTIONS –Drug Interactions).

Avoid the use of ketorolac tromethamine in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ketorolac tromethamine is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
BACKGROUND: Throughout history, the field of cytogenetics has witnessed significant changes due to the constant evolution of technologies used to assess chromosome number and structure. Similar to the evolution of single nucleotide variant detection from Sanger sequencing to next-generation sequencing, the identification of chromosome alterations has progressed from banding to fluorescence in situ hybridization (FISH) to chromosomal microarrays. More recently, emerging technologies such as optical genome mapping and genome sequencing have made noteworthy contributions to clinical laboratory testing in the field of cytogenetics.
CONTENT: In this review, we journey through some of the most pivotal discoveries that have shaped the development of clinical cytogenetics testing. We also explore the current test offerings, their uses and limitations, and future directions in technology advancements.
SUMMARY: Cytogenetics methods, including banding and targeted assessments like FISH, continue to hold crucial roles in cytogenetic testing. These methods offer a rapid turnaround time, especially for conditions with a known etiology involving recognized cytogenetic aberrations. Additionally, laboratories have the flexibility to now employ higher-throughput methodologies to enhance resolution for cases with greater complexity.
NEW MATERIAL:The 8beta-ergoline derivative of formula I and its acid addition salt. EXAMPLE:5-Methyl-1-(6-methyl-8beta-ergonylmethyl)-3-phenylpyrazole. USE:A drug. A preventive and remedy for hyperprolactinemia, Parkinson disease, etc. It has extremely low side effects such as emesis. It is administered by oral administration at a dose of 0.005-10mg/kg body weight per day. PREPARATION:The compound of formula I can be produced by reacting a compound of formula II (X is eliminable group consisting of an acid residue such as halogen and sulfonyloxy) with 3-methyl-5-phenylpyrazole or its metal salt in a solvent such as dimethyl formamide in the presence of a base such as NaH at 50-140 deg.C for formamide in the presence of a base such as NaH at 50-140 deg.C for 5min-15hr.
The present invention discloses a system and a method for providing and managing promotional and informational resources provided by drug manufacturers to HCPs. An HCP assistance system is disclosed having a static information repository with an information component that manipulates information recorded within the static information repository. HCP accessing the present invention are required to authenticate their membership in the system as well as their good standing with a licensing body. This authentication is performed within a presentation component that can be accessed via global computer network (GCN). An information component also provides an HCP with access to available drug samples, and any objective factual information related to a treatment, as well as any resources provided by pharmaceutical manufacturers to assist indigent patients. Additionally the system allows an HCP to participate in surveys and provide feedback to drug manufacturers, as well as to solicit or to decline future visits by sales representatives of a given drug manufacturer. Also disclosed is a preferred method for carrying out the present invention.
Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain the subject new substance, heteromonocyclic carboxylic acid esters, manifesting excellent hair growing effects, usable as the active ingredients in hair tonic composition. SOLUTION: The new substances are n-Pentadecyl-2-furoates of formula I, n-Pentadecyl-2-thenoates of formula II and Pentadecyltetrahydro-2-furoate of formula III. The substance of formula I has a molecular weight of 322, melting point of 36-37 deg.C and brown colored crystal at normal temperature. The compound of formula II is a new substance having a molecular weight of 338, a transparent oily substance at normal temperature. The new substance of formula III has a molecular weight of 326, a transparent oily substance at normal temperature. The new substances of formulae I to III are obtained by an esterification of n-pentadecanol with either one of 2-furoic acid of formula IV, thenoic acid of formula V, tetrahydro-2-furoic acid of formula VI.
Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
PURPOSE:A hair tonic that contains laver, black sesami, active essence of aloe, when needed, additionally essence of laurel leaves, thus being used to allow hairs developed by an emerging agent to grow and prevent the hairs from being lost or becoming white. CONSTITUTION:A sheet of laver, about 2g in weight, is crushed into fine pieces and boiled together with 5g of of black sesamis previously rinsed with water in 200cc of water, homogenized with a mixer for about 20min and squeezed through cotton cloth. Then, 200cc of water are added, they are sterilized by boiling with weak fire, then 1g of salt is added and the fire is stopped. Then, raw squeeze of aloe 20cc is added (5% of water) and 40cc of ethanol (10% of water) are added and they are cooled down to give the hair tonic solution. When the essence of laurel leaves is added, it is added together with the aloe raw squeeze by 30cc, after the fire is stopped. The hair-tonic solution is used at a rate of 60-70cc per month.
Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
A system, technique and material composition for use in correction of eye condition are disclosed. The system comprising a processing utility and an etching utility. The processing utility comprises: correction pattern module configured for providing a selected two-dimensional pattern in according with input data indicative of vision impermanent of a user, and for generating operational instructions for forming said selected two-dimensional pattern on the surface of the cornea by said etching utility. The etching utility is configured to etching the selected patter on surface of the cornea of a user. The material composition comprises aqueous solution comprising a plurality of nanoparticles, said nanoparticles comprising maghemite nanoparticles wrapped by biocompatible protein chains. The material composition may be used as eye drops thereby allowing the nanoparticles to occupy etched region on the cornea, thereby maintaining correction of eye condition.
Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because of their multifactorial origin. SHP2 is a ubiquitous tyrosine phosphatase that regulates major signalling pathways (e.g. MAPK, PI3K) in response to many growth factors. The inventors evaluate whether chronic inhibition of SHP2 could improve insulin sensitivity in animal models. Obese diabetic mice were thus treated by gavage (50 mg/kg/day). And the inventors note a significant improvement in the glucose tolerance of the treated animals compared to their control, with a decreased fasting blood glucose, without any change in weight or body composition. Accordingly, the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance.
Studies in Malawi, Egypt, and Nepal suggest that neonatal skin cleansing with chlorhexidine solutions may reduce the risk of infection and mortality. Cleansing with 0.25% chlorhexidine in Nepal resulted in a 28% reduction in mortality among low birth weight infants, while there was no impact on infants of normal weight. The mechanism of action for this observed benefit is not clear. Chlorhexidine may remove pathogens from the skin of the newborn and/or prevent exposure to pathogens that may otherwise cause infection and lead to sepsis. The benefit of chlorhexidine cleansing may be extended with higher concentrations of chlorhexidine.

Infants born at the Tribhuvan University Teaching Hospital in Katmandu, Nepal will be randomized to skin cleansing with chlorhexidine at one of three concentrations (0.25%, 0.50%, 1.00%). Skin swabs will be collected before wiping, and two and twenty-four hours after wiping in order to compare levels of bacteria on the skin across the treatment groups. A small quantity of blood will be collected at 24 hours after wiping to determine the potential for absorption of chlorhexidine
The G protein-coupled bile acid receptor 1 (GPBAR1) or TGR5 is widely distributed across organs, including the small intestine, stomach, liver, spleen, and gallbladder. Many studies have established strong correlations between TGR5 and glucose homeostasis, energy metabolism, immune-inflammatory responses, and gastrointestinal functions. These results indicate that TGR5 has a significant impact on the progression of tumor development and metabolic disorders such as diabetes mellitus and obesity. Targeting TGR5 represents an encouraging therapeutic approach for treating associated human ailments. Notably, the GLP-1 receptor has shown exceptional efficacy in clinical settings for diabetes management and weight loss promotion. Currently, numerous TGR5 agonists have been identified through natural product-based approaches and virtual screening methods, with some successfully progressing to clinical trials. This review summarizes the intricate relationships between TGR5 and various diseases emphasizing recent advancements in research on TGR5 agonists, including their structural characteristics, design tactics, and biological activities. We anticipate that this meticulous review could facilitate the expedited discovery and optimization of novel TGR5 agonists.
A system and method for entrainment of a user based on bio rhythm of the user. The system includes an analyzing unit and an entraining rhythm generation unit. The analyzing unit receives bio rhythm information of a user, analyzes the bio rhythm information, and sets an entraining target based on an analysis of the bio rhythm information. The entraining rhythm generation unit generates an entraining rhythm based on the entraining target for providing an entrainment experience to the user, and control one or more human sensory inputs to the user based on the entraining rhythm. The bio-rhythm information may be information related to a breathing rate, a heart rate, brain waves, circadian rhythm, body rhythm, emotion, etc. The entrainment experience may be provided either inside or outside a vehicle.
INTRODUCTION: Pain experience, physical reaction, image quality and adverse events during Gel Instillation Sonohysterography (GIS) can differ using gels with different compositions. As a result, patient satisfaction can also be affected. The effect of two instillation gels, Endosgel versus ExEmgel, using both the Visual Analogue Scale (VAS) and a Continuous Pain Score Meter (CPSM) was therefore compared.
METHODS: This single centre double blind randomised controlled trial included 80 women planned for outpatient GIS, diagnosed with abnormal intrauterine bleeding or fertility disorders and suspicion on an intrauterine abnormality. Patients were randomly allocated to the instillation of Endosgel containing chlorhexidine or ExEmgel without chlorhexidine. Primary outcome was reported pain during the procedure using VAS. Secondary outcomes included pain score measured using CPSM, satisfaction to the procedure and preference at 3 weeks and 3 months after the procedure and image quality. A cost benefit analysis was also performed.
RESULTS: The reported median VAS concerning pain during gel instillation was comparable in the Endosgel and ExEmgel group, 2.50 (IQR 0.00-5.00) and 2.00 (IQR 0.00-5.75) respectively (p = 0.69). The median VAS of the entire procedure was also similar: both 2.00 (IQR 0.00-5.00) (p = 0.86). CPSM-scores were not significantly different either. Both groups were similar in image quality (p = 0.83) and patient's satisfaction (p = 0.36).
CONCLUSION: Concerning the pain experienced during a GIS procedure and patients' satisfaction, the ExEmgel was not proven to be superior to the Endosgel. Our advice is to use the gel that is available at the lowest costs, as the image quality is the same for both Endosgel and ExEmgel.